Compare NGNE & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | NATH |
|---|---|---|
| Founded | 2003 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 418.8M |
| IPO Year | 2014 | 1996 |
| Metric | NGNE | NATH |
|---|---|---|
| Price | $35.40 | $101.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $63.57 | N/A |
| AVG Volume (30 Days) | ★ 219.9K | 20.3K |
| Earning Date | 05-08-2026 | 06-09-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ 4.85 |
| Revenue | N/A | ★ $104,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.91 |
| Revenue Growth | N/A | ★ 7.81 |
| 52 Week Low | $15.93 | $88.67 |
| 52 Week High | $37.27 | $117.49 |
| Indicator | NGNE | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 51.38 |
| Support Level | $19.27 | $100.32 |
| Resistance Level | $36.37 | $101.76 |
| Average True Range (ATR) | 2.05 | 0.63 |
| MACD | 0.39 | -0.02 |
| Stochastic Oscillator | 95.22 | 60.98 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.